Accordingly, there is no evidence for the proposition that costly or patented medicines are automatically excluded from the WHO-EML. The Expert Committee explicitly says that it does not consider and discriminate based on patent status, and if it does so implicitly, there is a transparent procedure in which anyone can apply to correct that.